Ocular Therapeutix, Inc.
OCULDrugs in Pipeline
15
Phase 3 Programs
9
Upcoming Catalysts
4
Next Catalyst
Aug 4, 2026
4wMarket Overview
Stock performance and key metrics
4 upcoming, 1 past
How OCUL's past catalysts played out
Aflibercept
Neovascular Age-related Macular Degeneration
OTX-TKI (axitinib implant)
Neovascular Age-Related Macular Degeneration
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24
Non-Proliferative Diabetic Retinopathy
Ophthalmic Insert
Open Angle Glaucoma and Ocular Hypertension
Dextenza Ophthalmic Insert
Cataract
Travoprost
Open Angle Glaucoma
Dexamethasone, 0.4mg
Allergic Conjunctivitis
Dexamethasone
Post-Surgical Ocular Pain
Punctum Plug
Post Ocular Surgical Inflammation and Pain
OTX-TP
Glaucoma
OTX-TIC low dose Travoprost Intracameral Implant
Open Angle Glaucoma
OTX-CSI
Dry Eye Disease
OTX-DED
Dry Eye
OTX-DP (Dexamethasone punctum plug)
Ocular Inflammation and Pain
Controlled Insertion
Dry Eye Syndromes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aflibercept | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
OTX-TKI (axitinib implant) | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 | Phase 3 | Non-Proliferative Diabetic Retinopathy | - | - |
Ophthalmic Insert | Phase 3 | Open Angle Glaucoma and Ocular Hypertension | - | - |
Dextenza Ophthalmic Insert | Phase 3 | Cataract | - | - |
Travoprost | Phase 3 | Open Angle Glaucoma | - | - |
Dexamethasone, 0.4mg | Phase 3 | Allergic Conjunctivitis | - | - |
Dexamethasone | Phase 3 | Post-Surgical Ocular Pain | - | - |
Punctum Plug | Phase 3 | Post Ocular Surgical Inflammation and Pain | - | - |
OTX-TP | Phase 2 | Glaucoma | - | - |
OTX-TIC low dose Travoprost Intracameral Implant | Phase 2 | Open Angle Glaucoma | - | - |
OTX-CSI | Phase 2 | Dry Eye Disease | - | - |
OTX-DED | Phase 2 | Dry Eye | - | - |
OTX-DP (Dexamethasone punctum plug) | Phase 2 | Ocular Inflammation and Pain | - | - |
Controlled Insertion | Phase 2 | Dry Eye Syndromes | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ocular Therapeutix, Inc.'s drug pipeline?→
CatalystAlert tracks 15 drug candidates in Ocular Therapeutix, Inc.'s (OCUL) pipeline across Phase 3, Phase 2. Its lead program is Aflibercept (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ocular Therapeutix, Inc.'s next FDA catalyst?→
Ocular Therapeutix, Inc.'s (OCUL) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OCUL biotech catalysts?→
Add OCUL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ocular Therapeutix, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.